Stryker Corporation (SYK) Expected to Earn FY2018 Earnings of $7.08 Per Share
Stryker Corporation (NYSE:SYK) – Research analysts at Leerink Swann issued their FY2018 earnings per share (EPS) estimates for shares of Stryker Corporation in a research report issued to clients and investors on Tuesday. Leerink Swann analyst R. Newitter anticipates that the brokerage will post earnings per share of $7.08 for the year.
Other analysts also recently issued research reports about the stock. Zacks Investment Research raised shares of Stryker Corporation from a “hold” rating to a “buy” rating and set a $119.00 price target for the company in a research report on Tuesday, November 15th. SunTrust Banks, Inc. started coverage on shares of Stryker Corporation in a research report on Thursday, October 13th. They set a “buy” rating and a $140.00 price target for the company. Canaccord Genuity set a $127.00 price objective on shares of Stryker Corporation and gave the stock a “buy” rating in a report on Sunday, October 30th. RBC Capital Markets reaffirmed a “buy” rating and issued a $129.00 price objective on shares of Stryker Corporation in a report on Friday, January 6th. Finally, Edward Jones downgraded shares of Stryker Corporation from a “buy” rating to a “hold” rating in a report on Thursday, January 5th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and thirteen have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $122.95.
Shares of Stryker Corporation (NYSE:SYK) traded down 0.28% during trading on Friday, reaching $122.92. 1,665,148 shares of the company’s stock were exchanged. Stryker Corporation has a 52 week low of $88.57 and a 52 week high of $127.23. The company’s 50-day moving average is $117.65 and its 200 day moving average is $116.10. The stock has a market capitalization of $46.03 billion, a PE ratio of 27.97 and a beta of 0.84.
Stryker Corporation (NYSE:SYK) last announced its quarterly earnings data on Thursday, October 27th. The medical technology company reported $1.39 EPS for the quarter, topping the Zacks’ consensus estimate of $1.37 by $0.02. The company earned $2.83 billion during the quarter, compared to the consensus estimate of $2.81 billion. Stryker Corporation had a net margin of 15.24% and a return on equity of 23.61%. Stryker Corporation’s quarterly revenue was up 17.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.25 EPS.
A number of large investors have recently modified their holdings of the company. Meag Munich Ergo Kapitalanlagegesellschaft MBH boosted its stake in shares of Stryker Corporation by 444.7% in the second quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 165,225 shares of the medical technology company’s stock valued at $19,667,000 after buying an additional 134,892 shares during the period. Ngam Advisors L.P. boosted its stake in shares of Stryker Corporation by 217.3% in the second quarter. Ngam Advisors L.P. now owns 77,132 shares of the medical technology company’s stock valued at $9,243,000 after buying an additional 52,821 shares during the period. Morgan Stanley boosted its stake in shares of Stryker Corporation by 18.2% in the third quarter. Morgan Stanley now owns 1,736,695 shares of the medical technology company’s stock valued at $202,167,000 after buying an additional 267,491 shares during the period. BlackRock Inc. boosted its stake in shares of Stryker Corporation by 1.3% in the third quarter. BlackRock Inc. now owns 803,398 shares of the medical technology company’s stock valued at $93,523,000 after buying an additional 10,305 shares during the period. Finally, Capstone Asset Management Co. boosted its stake in shares of Stryker Corporation by 3.4% in the third quarter. Capstone Asset Management Co. now owns 44,209 shares of the medical technology company’s stock valued at $5,146,000 after buying an additional 1,435 shares during the period. Hedge funds and other institutional investors own 74.89% of the company’s stock.
In other Stryker Corporation news, Director Ronda E. Stryker sold 5,194 shares of the business’s stock in a transaction dated Wednesday, December 28th. The shares were sold at an average price of $120.60, for a total value of $626,396.40. Following the sale, the director now directly owns 193,142 shares in the company, valued at $23,292,925.20. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Chairman Kevin Lobo sold 26,306 shares of the business’s stock in a transaction dated Thursday, November 3rd. The stock was sold at an average price of $115.74, for a total transaction of $3,044,656.44. The disclosure for this sale can be found here. Corporate insiders own 7.80% of the company’s stock.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, January 31st. Investors of record on Friday, December 30th will be paid a dividend of $0.425 per share. This is a boost from Stryker Corporation’s previous quarterly dividend of $0.38. This represents a $1.70 dividend on an annualized basis and a dividend yield of 1.38%. The ex-dividend date is Wednesday, December 28th. Stryker Corporation’s payout ratio is currently 38.72%.
About Stryker Corporation
Stryker Corporation (Stryker) is a medical technology company. The Company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Company’s Orthopaedics segment products consist of implants used in hip and knee joint replacements and trauma and surgeries. The Company’s MedSurg segment products consist of surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical), and reprocessed and remanufactured medical devices (Sustainability), as well as other medical device products used in a range of medical specialties.
Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.